J&J unblinds prostate cancer drug study; Aegerion names new CEO

@FierceBiotech: Four drugs look to pass FDA muster this month. Report | Follow @FierceBiotech

@JohnCFierce: Seattle Genetics CEO did a good job softening the blow on its trial failure; shares down about 18% anyway. | Follow @FierceBiotech

> J&J decided to unblind its Phase III study of the prostate cancer drug abiraterone acetate after the monitoring committee determined that the patients in the placebo group should be offered the therapy. The trial enrolled 1,195 patients. Report

> Aegerion Pharmaceuticals named Marc Beer, the founding CEO of ViaCell, as both CEO and a member of the board of directors. Aegerion release

> Ariad Pharmaceuticals and Cyclacel Pharmaceuticals each announced plans to move blood cancer therapies into late-stage trials. Story

> Athersys is pocketing a $3 million upfront after it agreed to provide RTI Biologics access to its Multipotent Adult Progenitor Cell technologies. RTI release

And Finally... Scientists say they've found a plant that can clone itself in order to survive environmental chaos, a helpful lesson for surviving climate change. Story

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.